Rothschild, Harriet T. http://orcid.org/0000-0001-5311-2872
Clelland, Elle http://orcid.org/0000-0003-1439-0532
Patterson, Anne http://orcid.org/0000-0002-1416-7376
Molina-Vega, Julissa
Kaur, Mandeep http://orcid.org/0000-0002-5544-5918
Symmans, W. Fraser http://orcid.org/0000-0002-1526-184X
Schwartz, Christopher J. http://orcid.org/0000-0002-8086-8429
Chien, A. Jo http://orcid.org/0000-0003-2978-6249
Mukhtar, Rita A. http://orcid.org/0000-0001-8079-7846
Funding for this research was provided by:
National Cancer Institute (K08CA256047)
National Center for Advancing Translational Sciences (TL1 TR 001871)
Article History
Received: 18 November 2022
Accepted: 13 March 2023
First Online: 5 April 2023
Declarations
:
: Dr. Symmans’ holds licensed invention patents (not related to this research) founder equity in Delphi Diagnostics, owns shares in IONIS Pharmaceuticals and Eiger Biopharmaceuticals, research funding from Pfizer, consultant to Astra Zeneca. A. Jo Chien receives research funding from Merck, Puma, Amgen, and Seattle Genetics. All other authors have no financial or non-financial conflict of interests to disclose.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the IRB of the University of California, San Francisco (17–23,655, January 16, 2020).
: Informed consent requirement was waived by the IRB, as no subjects were contacted for this study.
: Consent for publication was waived by the IRB, as no subjects were contacted for this study.